PT-141, also known as Bremelanotide or Vyleesi, is a synthetic peptide developed from the melanocortin receptor agonist family. It is structurally related to the alpha-melanocyte-stimulating hormone (α-MSH) and was initially synthesized for its potential effects on sexual arousal. The compound is typically synthesized through solid-phase peptide synthesis, a method that allows for the precise assembly of amino acids into the desired peptide sequence. Researchers have primarily investigated PT-141 for its effects on sexual dysfunction, particularly in premenopausal women with hypoactive sexual desire disorder (HSDD). Studies have shown that PT-141 can enhance sexual desire and arousal, leading to its approval for use in certain populations. It has also been explored for potential applications in male erectile dysfunction, although this is not its primary indication. The mechanism of action of PT-141 involves the activation of melanocortin receptors, particularly MC3R and MC4R, in the central nervous system. This activation is believed to influence pathways associated with sexual arousal and desire, although the exact neural mechanisms remain an area of active research. Pharmacokinetically, PT-141 has a half-life of approximately 2 to 4 hours when administered subcutaneously. It is known for its rapid onset of action, with effects typically observed within 30 minutes to an hour. The compound is stable when stored appropriately, but its bioavailability is limited when administered orally. Currently, PT-141 is approved by the FDA for the treatment of HSDD in premenopausal women under the brand name Vyleesi. It is not approved for use in men or for other indications. Ongoing research continues to explore its broader therapeutic potential and long-term safety profile.